Peihao Zheng

Preliminary results of CAR-T–based consolidation with or without ASCT for patients with relapsed/refractory large B-cell lymphoma in complete remission after salvage therapy

Fei Xue, Rui Liu, Huazhou Shi, Hui Shi et autres

CAR-T therapy, alone or combined with autologous stem cell transplantation (ASCT), is used as consolidation in relapsed/refractory large B-cell lymphoma (r/r LBCL) patients achieving complete remission (CR) after salvage therapy. However, the relative contributions of these approaches to long-term disease control in …

cn (code pays fourni par la source)

Antigen-switch and BCR-axis–enriched multi-target CAR T re-infusion after prior CAR T failure in R/R B-cell NHL.

Peihao Zheng, Yajing Zhang, Fangfang Cheng

e19017 Background: Relapse after CAR T-cell therapy remains a critical unmet need in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL), frequently associated with antigen escape and limited effective salvage options. We evaluated a non–single-antigen approach emphasizing antigen/construct switching beyond conventional CD19-only retreatment, incorporating …

cn (code pays fourni par la source)

Overcoming resistance to prior CAR-T therapy: Efficacy and safety of a sequential, multi-antigen targeted CAR T-cell strategy in B-cell NHL.

Guoai Su, Fangfang Cheng, Huihui Zhao, Peihao Zheng et autres

7021 Background: Relapse following CAR T-cell therapy is a significant unmet need for patients with B-cell non-Hodgkin lymphoma (B-NHL). Strategies to effectively salvage these patients are urgently required. We report the results of a prospective study evaluating a novel approach of sequential …

cn, kr (code pays fourni par la source)

Unveiling the “second wave”: Viral-triggered biphasic CAR-T expansion drives late-onset IEC-HS: Characterization and successful management

Guoai Su, Peihao Zheng, Xuelin Han, Yue Wu et autres

Abstract Background: While cytokine release syndrome (CRS) and ICANS are well-defined acute toxicities of CAR-T cell therapy, the landscape of late-onset complications is still evolving. A distinct and life-threatening hyper-inflammatory syndrome, now recognized as Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS), can …

Prolonged thrombocytopenia following diverse CAR-T cell therapies: High incidence, inflammatory risk factors, and a comparative efficacy analysis of TPO-receptor agonist strategies in a real-world cohort

Guoai Su, Peihao Zheng, Han Xue-lin, Rui-Jie He et autres

Abstract Background: Prolonged thrombocytopenia (PT) is a major toxicity following chimeric antigen receptor (CAR) T-cell therapy, increasing hemorrhagic risk and limiting subsequent treatments. The etiology is complex, extending beyond lymphodepletion to include a CAR-T-induced inflammatory state within the bone marrow. We hypothesize …

cn (code pays fourni par la source)

Chimeric antigen receptor (CAR) -T cell therapy treatment Richter's transformation

Shaomei Feng, Peihao Zheng, Haidi Liu, Sun Meiling et autres

Background/purpose: Despite advances in chronic lymphocytic leukemia treatment, effective therapies for cases with Richter's transformation (RT) are urgently needed. This study aimed to investigate the use of chimeric antigen receptor (CAR)-T cell infusion for RT. Methods: This study included RT patients at …

cn (code pays fourni par la source)

Sequential CD19-20 CAR T-cell therapy for refractory/relapsed diffuse large B-cell lymphoma

Zhonghua Fu, Peihao Zheng, Fan Yang, Shaomei Feng et autres

cn, us (code pays fourni par la source)

Whole brain radiotherapy combined with CART-cell therapy for relapsed/refractory central nervous system B-cell lymphoma

Hui Shi, Peihao Zheng, Zhonghua Fu, Miaomiao Cao et autres

Relapsed or refractory central nervous system B-cell lymphoma (r/r CNS-BL), including primary central nervous system lymphoma (PCNSL) and secondary central nervous system lymphoma (SCNSL), remains a significant therapeutic challenge with limited treatment options and poor prognosis. This study investigated the combination of …

cn, fr, us (code pays fourni par la source)

Efficacy and Safety of CART Cell Therapy in Aggressive B‐Cell Lymphomas Involving the Gastrointestinal Tract

Lixia Ma, Yimeng Dou, Rui Liu, Teng Xu et autres

OBJECTIVE: Currently, chimeric antigen receptor T-cell (CART) therapy represents a highly effective approach for relapsed/refractory B-cell lymphomas. However, it also carries treatment-related risks. Limited data are available on the risks associated with CART therapy in patients with gastrointestinal involvement in B-cell lymphomas. …

cn (code pays fourni par la source)

Central nervous system posttransplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation successfully treated with combination therapy of acalabrutinib and immunochemotherapy: A case report and literature review

Peihao Zheng, Teng Xu, Xiaona Zuo, Xiaoyan Ke et autres

Here, we report a case of Epstein-Barr virus-positive central nervous system-post-transplant lymphoproliferative disorder (CNS-PTLD) patient who failed to achieve complete metabolic remission (CMR) after successively trying a methotrexate-based regimen combined with orelabrutinib or whole-brain radiotherapy and encountered intracranial hemorrhage during orelabrutinib treatment. …

cn (code pays fourni par la source)

BCMA CAR-T induces complete and durable remission in plasmablastic lymphoma synchronous transformation of chronic lymphocytic leukemia: Case report and literature review

Shaomei Feng, Yu Xiong, Weicheng Liu, Haidi Liu et autres

Richter transformation is still a serious risk in the era of innovative therapies, despite the fact that targeted therapy with Bruton's tyrosine kinase inhibitor has significantly improved the prognosis for chronic lymphocytic leukemia (CLL). We report a rare case of a 61-year-old …

cn, us (code pays fourni par la source)

Salvage CD20-SD-CART therapy in aggressive B-cell lymphoma after CD19 CART treatment failure

Fei Xue, Peihao Zheng, Fan Yang, Rui Liu et autres

Background and aims: Patients with relapsed/refractory aggressive B-cell lymphoma(r/r aBCL)who progressed after CD19-specific chimeric antigen receptor T-cell therapy (CD19CART) had a poor prognosis. Application of CAR T-cells targeting a second different antigen (CD20) expressed on the surface of B-cell lymphoma as subsequent …

cn (code pays fourni par la source)